S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Details
Age
Adult
Type of Study
Treatment
Locations
Rocky Mountain Regional VA Medical Center
Principal Investigator
Jessica Mcdermott, MD
Study ID
Protocol Number: 22-2225
More information available at ClinicalTrials.gov: NCT05136196
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers